+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bispecific Antibodies"

From
Anti-CD38 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD38 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • March 2025
  • 60 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • March 2025
  • 450 Pages
  • Global
From
Complement Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Complement Inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 180 Pages
  • Global
From
From
From
Biliary Tumor - Pipeline Insight, 2024 - Product Thumbnail Image

Biliary Tumor - Pipeline Insight, 2024

  • Clinical Trials
  • July 2024
  • 180 Pages
  • Global
From
Hepatic Tumor - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatic Tumor - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 240 Pages
  • Global
From
Nasopharyngeal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Nasopharyngeal Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Gastric Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Gastric Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 550 Pages
  • Global
From
Advanced Merkel cell carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Advanced Merkel cell carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Mesothelioma - Pipeline Insight, 2024 - Product Thumbnail Image

Mesothelioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 210 Pages
  • Global
From
Anti-CD20 antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD20 antibody - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Acquired Hemophilia A - Pipeline Insight, 2024 - Product Thumbnail Image

Acquired Hemophilia A - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 50 Pages
  • Global
From
Vulvar Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Vulvar Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 70 Pages
  • Global
From
From
Bispecific Antibodies for Cancer Market 2025-2029 - Product Thumbnail Image

Bispecific Antibodies for Cancer Market 2025-2029

  • Report
  • February 2025
  • 233 Pages
  • Global
From
Loading Indicator

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases. Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments. The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more